Advanced Medical Isotope Corporation Appoints Dr. Darrell R. Fisher to its Medical Advisory Board
KENNEWICK, Wash., June 5, 2014 /PRNewswire/ — Advanced Medical Isotope Corporation (“AMIC”) (OTCBB: ADMD), a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications, today announced that Dr. Darrell R. Fisher has been appointed to the AMIC Medical Advisory Board, joining Chairman Dr. Barry D. Pressman.
Dr. Fisher is known internationally for his expertise in the dosimetry and consequences of exposure to radioactive materials, including medically administered radiopharmaceuticals for diagnostic and therapeutic benefit. Dr. Fisher is president of the Health Physics Society, an international organization of professionals engaged in the science and practice of radiation safety. He is a principal nuclear medicine dosimetrist with the Dade Moeller Health Group, Richland, Washington, a leading medical physics services provider. Dr. Fisher is a Fellow of the Health Physics Society and a recipient of its prestigious Elda Anderson Award. He also serves on the Medical Internal Radiation Dose Committee of the Society of Nuclear Medicine and Molecular Imaging, which develops standard methods for radiopharmaceutical dosimetry.
Dr. Fisher previously served on the U.S. Nuclear Regulatory Commission’s Advisory Committee on the Medical Uses of Isotopes. He recently completed a 35-year career at the Pacific Northwest National Laboratory (PNNL), where he led the Isotope Sciences Program. He holds six patents, including patents licensed by AMIC for its brachytherapy products.
AMIC CEO, Chairman and Founder James C. Katzaroff remarked: “I am delighted that after many years of working together on our yttrium-90 brachytherapy product line, Dr. Fisher has joined our Medical Advisory Board. I believe that Dr. Fisher’s expertise in dosimetry and the health effects of radiation as well as his extensive technical knowledge of our yttrium-90 brachytherapy products, will prove invaluable to AMIC’s product commercialization efforts.”
About Advanced Medical Isotope Corporation
Advanced Medical Isotope Corporation (OTCBB: ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC’s focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website: www.isotopeworld.com.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, AMIC’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.
SOURCE Advanced Medical Isotope Corporation